EdgarLookup

LINDSAY CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that LINDSAY CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
10.9%
Profit Margin
Net income ÷ revenue
8.8%
Return on Assets
Net income ÷ assets
0.58x
Debt-to-Equity
Total liabilities ÷ equity
+11.4%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $676.37M Oct 23, 2025
FY2024 Aug 31, 2024 $607.07M Oct 23, 2025
FY2024 Aug 31, 2023 $674.08M Oct 23, 2025
FY2024 Aug 31, 2022 $770.74M Oct 24, 2024
FY2023 Aug 31, 2021 $567.65M Oct 19, 2023
FY2020 Aug 31, 2020 $128.41M Oct 22, 2020
FY2020 May 31, 2020 $123.11M Oct 22, 2020
FY2020 Feb 29, 2020 $113.79M Oct 22, 2020
FY2020 Nov 30, 2019 $109.39M Oct 22, 2020
FY2020 Aug 31, 2019 $101.89M Oct 22, 2020

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $659.07M Oct 23, 2025
FY2024 Aug 31, 2024 $584.26M Oct 23, 2025
FY2024 Aug 31, 2023 $661.91M Oct 23, 2025
FY2024 Aug 31, 2022 $760.26M Oct 24, 2024
FY2022 Aug 31, 2021 $551.28M Oct 20, 2022
FY2021 Aug 31, 2020 $463.21M Oct 21, 2021
FY2020 Aug 31, 2019 $436.32M Oct 22, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $210.78M Oct 23, 2025
FY2024 Aug 31, 2024 $191.06M Oct 23, 2025
FY2024 Aug 31, 2023 $213.02M Oct 23, 2025
FY2024 Aug 31, 2022 $199.18M Oct 24, 2024
FY2023 Aug 31, 2021 $150.21M Oct 19, 2023
FY2022 Aug 31, 2020 $152.54M Oct 20, 2022
FY2021 Aug 31, 2019 $114.61M Oct 21, 2021
FY2020 Aug 31, 2018 $151.46M Oct 22, 2020
FY2019 Aug 31, 2017 $145.01M Oct 31, 2019
FY2018 Aug 31, 2016 $148.61M Oct 24, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $74.05M Oct 23, 2025
FY2024 Aug 31, 2024 $66.26M Oct 23, 2025
FY2024 Aug 31, 2023 $72.38M Oct 23, 2025
FY2024 Aug 31, 2022 $65.47M Oct 24, 2024
FY2023 Aug 31, 2021 $42.57M Oct 19, 2023
FY2020 Aug 31, 2020 $14.67M Oct 22, 2020
FY2020 May 31, 2020 $10.09M Oct 22, 2020
FY2020 Feb 29, 2020 $5.52M Oct 22, 2020
FY2020 Nov 30, 2019 $8.35M Oct 22, 2020
FY2020 Aug 31, 2019 $1.50M Oct 22, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $88.12M Oct 23, 2025
FY2024 Aug 31, 2024 $76.61M Oct 23, 2025
FY2024 Aug 31, 2023 $102.18M Oct 23, 2025
FY2024 Aug 31, 2022 $94.64M Oct 24, 2024
FY2023 Aug 31, 2021 $54.11M Oct 19, 2023
FY2022 Aug 31, 2020 $54.20M Oct 20, 2022
FY2021 Aug 31, 2019 $6.12M Oct 21, 2021
FY2020 Aug 31, 2018 $39.01M Oct 22, 2020
FY2019 Aug 31, 2017 $40.65M Oct 31, 2019
FY2018 Aug 31, 2016 $34.38M Oct 24, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $17.93M Oct 23, 2025
FY2024 Aug 31, 2024 $17.12M Oct 23, 2025
FY2024 Aug 31, 2023 $18.22M Oct 23, 2025
FY2024 Aug 31, 2022 $15.15M Oct 24, 2024
FY2023 Aug 31, 2021 $13.36M Oct 19, 2023
FY2022 Aug 31, 2020 $13.95M Oct 20, 2022
FY2021 Aug 31, 2019 $13.94M Oct 21, 2021
FY2020 Aug 31, 2018 $16.03M Oct 22, 2020
FY2019 Aug 31, 2017 $17.15M Oct 31, 2019
FY2018 Aug 31, 2016 $15.85M Oct 24, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $132.91M Oct 23, 2025
FY2024 Aug 31, 2024 $95.76M Oct 23, 2025
FY2024 Aug 31, 2023 $119.71M Oct 23, 2025
FY2024 Aug 31, 2022 $3.05M Oct 24, 2024
FY2023 Aug 31, 2021 $43.97M Oct 19, 2023
FY2022 Aug 31, 2020 $46.03M Oct 20, 2022
FY2021 Aug 31, 2019 $3.80M Oct 21, 2021
FY2020 Aug 31, 2018 $33.93M Oct 22, 2020
FY2019 Aug 31, 2017 $39.45M Oct 31, 2019
FY2018 Aug 31, 2016 $33.13M Oct 24, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $42.50M Oct 23, 2025
FY2024 Aug 31, 2024 $28.98M Oct 23, 2025
FY2024 Aug 31, 2023 $18.78M Oct 23, 2025
FY2024 Aug 31, 2022 $15.60M Oct 24, 2024
FY2023 Aug 31, 2021 $26.51M Oct 19, 2023
FY2022 Aug 31, 2020 $21.45M Oct 20, 2022
FY2021 Aug 31, 2019 $23.21M Oct 21, 2021
FY2020 Aug 31, 2018 $11.05M Oct 22, 2020
FY2019 Aug 31, 2017 $8.86M Oct 31, 2019
FY2018 Aug 31, 2016 $11.50M Oct 24, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $840.84M Oct 23, 2025
FY2024 Aug 31, 2024 $760.23M Oct 23, 2025
FY2024 Aug 31, 2023 $745.66M Oct 24, 2024
FY2023 Aug 31, 2022 $710.65M Oct 19, 2023
FY2022 Aug 31, 2021 $637.19M Oct 20, 2022
FY2021 Aug 31, 2020 $570.53M Oct 21, 2021
FY2020 Aug 31, 2019 $500.31M Oct 22, 2020
FY2020 Aug 31, 2018 $499.82M Oct 22, 2020
FY2019 Aug 31, 2017 $506.03M Oct 31, 2019
FY2018 Aug 31, 2016 $487.52M Oct 24, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $307.99M Oct 23, 2025
FY2024 Aug 31, 2024 $279.34M Oct 23, 2025
FY2024 Aug 31, 2023 $290.01M Oct 24, 2024
FY2023 Aug 31, 2022 $317.30M Oct 19, 2023
FY2022 Aug 31, 2021 $298.74M Oct 20, 2022
FY2021 Aug 31, 2020 $272.01M Oct 21, 2021
FY2020 Aug 31, 2019 $232.11M Oct 22, 2020
FY2019 Aug 31, 2018 $222.95M Oct 31, 2019
FY2018 Aug 31, 2017 $235.98M Oct 24, 2018
FY2017 Aug 31, 2016 $235.95M Oct 13, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $532.85M Oct 23, 2025
FY2024 Aug 31, 2024 $480.89M Oct 23, 2025
FY2024 Aug 31, 2023 $455.65M Oct 23, 2025
FY2024 Aug 31, 2022 $393.36M Oct 23, 2025
FY2024 Aug 31, 2021 $338.45M Oct 24, 2024
FY2023 Aug 31, 2020 $298.52M Oct 19, 2023
FY2022 Aug 31, 2019 $268.21M Oct 20, 2022
FY2021 Aug 31, 2018 $276.87M Oct 21, 2021
FY2020 Aug 31, 2017 $270.06M Oct 22, 2020
FY2019 Aug 31, 2016 $251.57M Oct 31, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $84.46M Oct 23, 2025
FY2024 Aug 31, 2024 $84.19M Oct 23, 2025
FY2024 Aug 31, 2023 $83.12M Oct 23, 2025
FY2024 Aug 31, 2022 $67.13M Oct 24, 2024
FY2023 Aug 31, 2021 $67.97M Oct 19, 2023
FY2022 Aug 31, 2020 $68.00M Oct 20, 2022
FY2021 Aug 31, 2019 $64.39M Oct 21, 2021
FY2020 Aug 31, 2018 $64.67M Oct 22, 2020
FY2019 Aug 31, 2017 $77.13M Oct 31, 2019
FY2018 Aug 31, 2016 $76.80M Oct 24, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $745.40M Oct 23, 2025
FY2024 Aug 31, 2024 $687.09M Oct 23, 2025
FY2024 Aug 31, 2023 $636.30M Oct 24, 2024
FY2023 Aug 31, 2022 $579.00M Oct 19, 2023
FY2022 Aug 31, 2021 $528.13M Oct 20, 2022
FY2021 Aug 31, 2020 $499.72M Oct 21, 2021
FY2020 Aug 31, 2019 $474.74M Oct 22, 2020
FY2019 Aug 31, 2018 $484.89M Oct 31, 2019
FY2018 Aug 31, 2017 $477.62M Oct 24, 2018
FY2017 Aug 31, 2016 $466.93M Oct 13, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $250.58M Oct 23, 2025
FY2024 Aug 31, 2024 $190.88M Oct 23, 2025
FY2024 Aug 31, 2023 $160.76M Oct 24, 2024
FY2023 Aug 31, 2022 $105.05M Oct 19, 2023
FY2022 Aug 31, 2021 $127.11M Oct 20, 2022
FY2021 Aug 31, 2020 $121.40M Oct 21, 2021
FY2020 Aug 31, 2019 $127.20M Oct 22, 2020
FY2019 Aug 31, 2018 $160.79M Oct 31, 2019
FY2018 Aug 31, 2017 $121.62M Oct 24, 2018
FY2018 Aug 31, 2016 $101.25M Oct 24, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 $115.26M Oct 23, 2025
FY2024 Aug 31, 2024 $115.49M Oct 23, 2025
FY2024 Aug 31, 2023 $115.71M Oct 24, 2024
FY2023 Aug 31, 2022 $115.93M Oct 19, 2023
FY2022 Aug 31, 2021 $116.15M Oct 20, 2022
FY2021 Aug 31, 2020 $116.34M Oct 21, 2021
FY2020 Aug 31, 2019 $116.57M Oct 22, 2020
FY2019 Aug 31, 2018 $116.78M Oct 31, 2019
FY2018 Aug 31, 2017 $116.98M Oct 24, 2018
FY2017 Aug 31, 2016 $117.17M Oct 13, 2017

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 6 Oct 23, 2025
FY2024 Aug 31, 2024 6 Oct 23, 2025
FY2024 Aug 31, 2023 6 Oct 23, 2025
FY2024 Aug 31, 2022 5 Oct 24, 2024
FY2023 Aug 31, 2021 3 Oct 19, 2023
FY2022 Aug 31, 2020 3 Oct 20, 2022
FY2021 Aug 31, 2019 0 Oct 21, 2021
FY2020 Aug 31, 2018 1 Oct 22, 2020
FY2019 Aug 31, 2017 2 Oct 31, 2019
FY2018 Aug 31, 2016 1 Oct 24, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2024 Aug 31, 2025 6 Oct 23, 2025
FY2024 Aug 31, 2024 6 Oct 23, 2025
FY2024 Aug 31, 2023 6 Oct 23, 2025
FY2024 Aug 31, 2022 5 Oct 24, 2024
FY2023 Aug 31, 2021 3 Oct 19, 2023
FY2020 Aug 31, 2020 1 Oct 22, 2020
FY2020 May 31, 2020 0 Oct 22, 2020
FY2020 Feb 29, 2020 0 Oct 22, 2020
FY2020 Nov 30, 2019 0 Oct 22, 2020
FY2020 Aug 31, 2019 0 Oct 22, 2020